| Benefits and risks of rapid initiation of antiretroviral therapy |
32 |
| Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency |
30 |
| HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer |
28 |
| Mental health and HIV/AIDS: the need for an integrated response |
28 |
| Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis |
27 |
| Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials |
27 |
| Global, regional and country-level 90-90-90 estimates for 2018: assessing progress towards the 2020 target |
21 |
| Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience |
20 |
| Transactional sex and incident HIV infection in a cohort of young women from rural South Africa |
19 |
| Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV: the mediating role of depression |
17 |
| A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients |
16 |
| Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago |
16 |
| Models of integration of HIV and noncommunicable disease care in sub-Saharan Africa: lessons learned and evidence gaps |
15 |
| The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe |
15 |
| Global HIV neurology: a comprehensive review |
14 |
| Neurodevelopment of breastfed HIV-exposed uninfected and HIV-unexposed children in South Africa |
14 |
| Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy |
14 |
| Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV |
14 |
| Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection |
14 |
| Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV |
14 |
| Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial |
13 |
| Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals |
13 |
| RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population |
13 |
| Vaginal microbiota and susceptibility to HIV |
13 |
| Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals |
13 |
| Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy |
13 |
| Do people living with HIV experience greater age advancement than their HIV-negative counterparts? |
12 |
| Is HIV patient navigation associated with HIV care continuum outcomes? |
12 |
| Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection |
12 |
| Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide |
12 |
| Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy |
11 |
| Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice |
11 |
| Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers |
11 |
| Experiences using and organizing HIV self-testing |
11 |
| Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV |
11 |
| Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV |
11 |
| Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy |
11 |
| Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals |
11 |
| Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects |
10 |
| We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in preexposure prophylaxis cohorts |
10 |
| Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients |
10 |
| Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use: results from the Amsterdam pre-exposure prophylaxis demonstration project |
10 |
| Differences in the rate of nicotine metabolism among smokers with and without HIV |
10 |
| Clinical trials of antiretroviral treatment interruption in HIV-infected individuals |
10 |
| HIV-infected cannabis users have lower circulating CD16(+) monocytes and IFN-gamma-inducible protein 10 levels compared with nonusing HIV patients |
10 |
| Integration of care for HIV and opioid use disorder |
10 |
| Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals |
10 |
| Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis |
9 |
| Perinatally acquired HIV infection accelerates epigenetic aging in South African adolescents |
9 |
| Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results |
9 |
